跳至主要内容
临床试验/NCT02014519
NCT02014519已完成不适用

Seroprevalence of Bordetella Pertussis in Adults in Hungary

GlaxoSmithKline6 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2014年4月24日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
2,000
试验地点
6
主要终点
Number of Seropositive Subjects in Terms of Anti-pertussis Toxin (Anti-PT) Concentrations

研究概览

简要总结

The purpose of this study is to perform an epidemiological survey of the adult population in Hungary to calculate the seroprevalence of pertussis.

详细描述

The protocol posting was amended to correct the detailed title. Since a sample of blood will be collected from all subjects (outside of routine hospital procedure), the study does not meet GSK's definition of an observational study and hence the term "observational" was deleted from the detailed title.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects who the investigator believes can and will comply with the requirements of the protocol.
  • Written informed consent will be obtained from subjects prior to performing any study procedures.
  • Males or females ≥ 18 years of age at the time of enrollment.
  • Agreeing to collection of a blood sample for the study.

排除标准

  • Confirmed or suspected immunological disorder.

结局指标

主要结局

Number of Seropositive Subjects in Terms of Anti-pertussis Toxin (Anti-PT) Concentrations

时间窗: At the time of enrollment of each subject (Day 0)

Seropositivity was defined as anti-PT IgG levels above the sensitivity limit of the assay (\> 0.3 Optical Density (OD) units)

Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection

时间窗: At the time of enrollment of each subject (Day 0)

The cut-off value for anti-PT IgG levels indicative of current/recent infection was greater than or equal to (≥) 1.0 OD units.

Number of Seronegative Subjects in Terms of Anti-PT Concentrations

时间窗: At the time of enrollment of each subject (Day 0)

Seronegativity was defined as anti-PT IgG levels under the sensitivity limit of the assay (≤ 0.3 OD units)

Number of Subjects With Anti-PT IgG Levels Strongly Indicative of Current/Recent Infection

时间窗: At the time of enrollment of each subject (Day 0)

The cut-off value for anti-PT IgG levels strongly indicative of current/recent infection was greater than or equal to (≥) 1.5 OD units

次要结局

  • Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Gender)(At the time of enrollment of each subject (Day 0))
  • Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by History of Pertussis)(At the time of enrollment of each subject (Day 0))
  • Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by History of Pertussis)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by History of Vaccination Against Pertussis)(At the time of enrollment of each subject (Day 0))
  • Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Medication)(At the time of enrollment of each subject (Day 0))
  • Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Age)(At the time of enrollment of each subject (Day 0).)
  • Number of Subjects With Anti-PT IgG Levels Strongly Indicative of Current/Recent Infection (by Age)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Age)(At the time of enrollment of each subject (Day 0))
  • Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Age)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Gender)(At the time of enrollment of each subject (Day 0))
  • Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Recent History of Long-lasting Cough)(At the time of enrollment of each subject (Day 0))
  • Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Recent History of Long-lasting Cough)(At the time of enrollment of each subject (Day 0))
  • Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Gender)(At the time of enrollment of each subject (Day 0))
  • Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Smoking Status)(At the time of enrollment of each subject (Day 0))
  • Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Smoking Status)(At the time of enrollment of each subject (Day 0))
  • Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by History of Vaccination Against Pertussis)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by History of Vaccination Against Pertussis)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Strongly Indicative of Current/Recent Infection (by Gender)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Gender)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Recent History of Long-lasting Cough)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Recent History of Long-lasting Cough)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Smoking Status)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Smoking Status)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by History of Pertussis)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by History of Pertussis)(At the time of enrollment of each subject (Day 0))
  • Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by History of Vaccination Against Pertussis)(At the time of enrollment of each subject (Day 0))
  • Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Medication)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Medication)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Medication)(At the time of enrollment of each subject (Day 0))
  • Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Hospitalization)(At the time of enrollment of each subject (Day 0))
  • Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Hospitalization)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Hospitalization)(At the time of enrollment of each subject (Day 0))
  • Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Hospitalization)(At the time of enrollment of each subject (Day 0))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验